Ramalingam SS, Dahlberg SE, Belani CP, et al. - In this randomized study, researchers investigated the optimal maintenance therapy between single-agent bevacizumab or pemetrexed vs combination of bevacizumab and pemetrexed for patients with advanced nonsquamous non–small-cell lung cancer (NSCLC). They administered carboplatin (area under the curve, 6), paclitaxel (200 mg/m²), and bevacizumab (15 mg/kg) for up to four cycles in patients with advanced nonsquamous NSCLC and no previous systemic therapy. Maintenance therapy with bevacizumab (15 mg/kg), pemetrexed (500 mg/m²), or a combination of the two agents was randomly received by patients without progression after four cycles. Overall survival was assessed as the primary endpoint, with bevacizumab serving as the control group. Findings revealed the efficacy of single-agent bevacizumab or pemetrexed as maintenance therapy for advanced nonsquamous NSCLC. Experts did not recommend the combination of bevacizumab and pemetrexed as maintenance therapy in these patients because of no survival benefit and rather higher toxicity associated with this treatment strategy.